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Primary immune thrombocytopenia (ITP) has been tradi-
tionally thought as an antibody-mediated autoimmune dis-
ease involving platelet destruction by macrophages in the
reticuloendothelia system. More recently it has become
obvious that ITP is a more complex disorder in which
T cell mediated immunity plays important roles in platelet
destruction. Antiplatelet autoantibody production is under
the control of platelet-specific helper T-cells, and loss of
tolerance to self antigen by T cells is the critical step of
the immune dysregulation in ITP. Dendritic cells (DCs)
from ITP patients showed enhanced capacity in stimulat-
ing autologous T-cell proliferation in the presence of auto-
logous/allogeneic platelets [1], and ITP patients’ T cells
had elevated IL-2 secretion ability compared with controls
[2,3], suggesting increased antiplaltelet T-cell reactivity in
ITP. The epitopes that recognize platelet glycoprotein
(GP) IIIa on T helper (Th) cells has been determined and
mapped by several groups [4,5], thus sheding new lights
on the “therapeutic vaccination” approach to reinstate tol-
erance in ITP. Autoreactive T-cell reactivity against plate-
let antigen in active ITP patients has been observed at
polyclonal as well as oligoclonal levels [6,7]. Our group
has demonstrated that blocking the B7-CD28 interaction
with CTLA4-Ig/CsA could induce platelet GP-specific
T-cell anergy, which could exert suppressive effect on GP-
reactive T cells via inducing tolerogenic dendritic cells
( D C s )[ 8 , 9 ] .I th a sb e e nw e l le s t a b l i s h e dt h a ta p o p t o t i c
genes, such as Fas, A20, Bax, Calpastatin, IL2RB, were
expressed aberrantly in patients with active ITP [10,11],
leading to autoreactive T cells resistant to activation
induced cell death (AICD), which could in turn support
the expansion of self-reactive T-cell clones. A loss of resis-
tant to AICD might be an important mechanism for the
achievement of remission in ITP. Previous studies have
revealed that dexamethasone could suppress T-cell prolif-
eration and induce apoptosis of T-cells in ITP [11,12]. In
addition, our group has demonstrated that a novel BAFF
blocking reagent, BR3-Fc, could restore the apoptosis of
both B and T cells [13]. Th polarization in ITP has been
attributed to increased Th1 [2,14], and Th17 cells [15] or
reduced number or function of CD4
+CD25
+Foxp3
+ T-reg-
ulatory cells (Tregs) [16,17]. A parallel body of aberrant
cytokine patterns, such as the elevated ratio of interleukin
(IL) -18/IL-18 binding protein (BP) [18,19], the increased
expression of B cell activating factor (BAFF) has been
reported in active ITP patients [20,21]. High-dose dex-
amthasone (HD-DXM) could not only restore Th1/Th2
[14] or IL-18/IL-18BP balance [19], but also increase the
number of Tregs [16], and inhibit the expression of BAFF
[12]. Besides HD-DXM, multiple agents, such as rituximab
[22], intravenous immunoglobulin (IVIg) [23], romiplos-
tim, eltrombopag [24] as well as indirubin [25], could
increase the number or restore the function of Tregs in
ITP. Our recently study showed that GP-specific induced
Tregs could be successfully generated de novo from non-
regulatory CD4
+CD25
-CD45RA
+ cells and could mediate
both antigen-specific and linked suppression of proliferat-
ing antiplatelet CD4
+ Th cells in vitro, and further
research revealed that the de novo expanded Tregs
mediated their suppressive effects on T cells via actually
modulating the T-cell stimulatory capacity of DCs [26],
thus providing a clue to the potential of producing anti-
gen-specific Tregs from the patients in vitro for the pur-
pose of antigen-targeted cellular immunotherapy. In
conclusion, induction of T-cell tolerance may provide a
useful strategy for the management of ITP.
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